A Phase 1, Randomized, Open-Label, 2-Way Crossover Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of Tofacitinib Following Single Oral Dose Of MR 11 mg Compared To MR 22 mg In Healthy Volunteers
Latest Information Update: 03 Jan 2013
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ankylosing spondylitis; Crohn's disease; Dry eyes; Plaque psoriasis; Psoriatic arthritis; Renal transplant rejection; Rheumatoid arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 21 Dec 2012 New trial record
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.